Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nilufer Bulut

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 28, 2015
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?Arife Ulas, Nilufer Avci, Tugba Kos, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 7, 2015
Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survivalArife Ulas, Tugba Kos, Nilufer Avci, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 3, 2025
Association between metabolic status and nivolumab efficacy in metastatic non-small cell lung cancer: Focus on resting energy expenditureTanju Kapagan, Nilufer Bulut, Gokmen Umut Erdem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgiaOmer Dizdar, Levent Ozçakar, Fevziye Unsal Malas, et al.
World Journal of Gastrointestinal Surgery|June 30, 2025
Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapyNilufer Bulut, Gokmen U Erdem, Tanju Kapagan, et al.
Medical Oncology (Northwood, London, England)|October 22, 2010
Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancerNilufer Bulut, Sercan Aksoy, Omer Dizdar, et al.
Journal of Biochemical and Molecular Toxicology|January 12, 2026
Quercetin Exhibits Nephroprotective Properties Against Tartrazine-Induced Nephrotic Injury: Effects on Oxidative Stress, Kidney Function, Inflammation, Renal Tissue Morphology, and Apoptotic PathwayZeynep Erdemli, Mehmet Gul, Nilufer Bulut, et al.
Journal of Biochemical and Molecular Toxicology|April 30, 2026
Ameliorative Effects of Quercetin on Tartrazine-Induced Hepatotoxicity in Rats: Insights Into Body Weight, Caspase Signaling, Cytokine Storm, Oxidative Stress, and Hepatocellular ProliferationBülent Aylaz, Zeynep Erdemli, Mehmet Gul, et al.
Journal of Biochemical and Molecular Toxicology|November 14, 2017
Synthesis of some novel pyridine compounds containing bis-1,2,4-triazole/thiosemicarbazide moiety and investigation of their antioxidant properties, carbonic anhydrase, and acetylcholinesterase enzymes inhibition profilesNilufer Bulut, Umit M Kocyigit, Ibrahim H Gecibesler, et al.
Journal of Clinical Medicine|March 14, 2026
Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 InhibitorsŞahin Bedir, Tanju Kapagan, Burçin Çakan Demirel, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 28, 2015
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?Arife Ulas, Nilufer Avci, Tugba Kos, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 7, 2015
Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survivalArife Ulas, Tugba Kos, Nilufer Avci, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 3, 2025
Association between metabolic status and nivolumab efficacy in metastatic non-small cell lung cancer: Focus on resting energy expenditureTanju Kapagan, Nilufer Bulut, Gokmen Umut Erdem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgiaOmer Dizdar, Levent Ozçakar, Fevziye Unsal Malas, et al.
World Journal of Gastrointestinal Surgery|June 30, 2025
Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapyNilufer Bulut, Gokmen U Erdem, Tanju Kapagan, et al.
Medical Oncology (Northwood, London, England)|October 22, 2010
Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancerNilufer Bulut, Sercan Aksoy, Omer Dizdar, et al.
Journal of Biochemical and Molecular Toxicology|January 12, 2026
Quercetin Exhibits Nephroprotective Properties Against Tartrazine-Induced Nephrotic Injury: Effects on Oxidative Stress, Kidney Function, Inflammation, Renal Tissue Morphology, and Apoptotic PathwayZeynep Erdemli, Mehmet Gul, Nilufer Bulut, et al.
Journal of Biochemical and Molecular Toxicology|April 30, 2026
Ameliorative Effects of Quercetin on Tartrazine-Induced Hepatotoxicity in Rats: Insights Into Body Weight, Caspase Signaling, Cytokine Storm, Oxidative Stress, and Hepatocellular ProliferationBülent Aylaz, Zeynep Erdemli, Mehmet Gul, et al.
Journal of Biochemical and Molecular Toxicology|November 14, 2017
Synthesis of some novel pyridine compounds containing bis-1,2,4-triazole/thiosemicarbazide moiety and investigation of their antioxidant properties, carbonic anhydrase, and acetylcholinesterase enzymes inhibition profilesNilufer Bulut, Umit M Kocyigit, Ibrahim H Gecibesler, et al.
Journal of Clinical Medicine|March 14, 2026
Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 InhibitorsŞahin Bedir, Tanju Kapagan, Burçin Çakan Demirel, et al.
Pageof 4